Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127137) titled 'Efficacy and Safety of Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection (rhTNK-tPA) Combined with Butylphthalide in the Treatment of Acute Ischemic Stroke: A Multicenter, Prospective, Real-World Registry Study (TROY Registry)' on June 25.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shanghai Tongren Hospital
Condition:
acute ischemic stroke
Intervention:
Long-course group: sequential therapy with rhTNK-tPA thrombolysis combined with butylphthalide (21-90 days):None
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-07-01
Targ...